Renaissance Technologies’s Altamira Therapeutics Ltd CYTO Stock Holding History

Renaissance Technologies’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50	Closed	-$6K	–	4516
2022 Q3	$6K	Buy	+50	New	+$8.3K	﹤0.01%	3970
2021 Q4	–	Sell	-178	Closed	-$143K	–	4315
2021 Q3	$143K	Buy	+178	New	+$201K	﹤0.01%	3268
2021 Q1	–	Sell	-158	Closed	-$165K	–	3819
2020 Q4	$165K	Buy	+158	New	+$102K	﹤0.01%	3179
2020 Q3	–	Sell	-143	Closed	-$54K	–	3786
2020 Q2	$54K	Buy	+143	New	+$53.7K	﹤0.01%	3334
2020 Q1	–	Sell	-114	Closed	-$74K	–	3916
2019 Q4	$74K	Buy	+114	New	+$77.3K	﹤0.01%	3354

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SCA

Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

Renaissance Technologies's CYTO Position: Q4 2022 in Review

Renaissance Technologies sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2022, closing a stake of 50 shares — an estimated $6K sold.

Renaissance Technologies first reported a position in CYTO in Q4 2019 and held it in 5 quarters. The position peaked at $165K in Q4 2020. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2022.

Renaissance Technologies reported no remaining Altamira Therapeutics Ltd position as of Q4 2022 after selling out during the quarter.
Renaissance Technologies sold 50 Altamira Therapeutics Ltd shares in Q4 2022, an estimated $6K.
Renaissance Technologies first reported a position in Altamira Therapeutics Ltd in Q4 2019 and held it in 5 quarters.
Renaissance Technologies's Altamira Therapeutics Ltd position peaked at $165K in Q4 2020.
6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.